Mersana Therapeutics, Inc. (MRSN)

$4.91

+0.03 (+0.61%)
Rating:
Recommendation:
Neutral
Symbol MRSN
Price $4.91
Beta 2.349
Volume Avg. 1.42M
Market Cap 476.227M
Shares () -
52 Week Range 2.68-14.8
1y Target Est -
DCF Unlevered MRSN DCF ->
DCF Levered MRSN LDCF ->
ROE -119.10% Strong Sell
ROA -70.71% Strong Sell
Operating Margin -
Debt / Equity 83.79% Buy
P/E -
P/B 2.79 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest MRSN news


Ms. Anna Protopapas
Healthcare
Biotechnology
NASDAQ Global Select

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.